Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1

Stroke

Volumn 37, Issue 9, 2006, Pages 2368-2371

  Wilczak, Nadine ^a   Elting, Jan Willem ^a   Chesik, Daniel ^a   Kema, Ido P ^a   De Keyser, Jacques ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute stroke; Insulin like growth factor 1; Neuroprotection; Thrombolysis; Tissue plasminogen activator

Indexed keywords

SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BIOAVAILABILITY; BRAIN ISCHEMIA; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; STROKE; THERAPY EFFECT;

AGED; AGED, 80 AND OVER; BIOLOGICAL AVAILABILITY; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; RADIOIMMUNOASSAY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33748342347     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000236496.30106.4b     Document Type: Article

References (20)

1. Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005;26:916-943.
2. Guan J, Bennet L, Gluckman PD, Gunn AJ. Insulin-like growth factor-1 and post-ischemic brain injury. Prog Neurobiol. 2003;70:443-462.
3. Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 1994;42:140-144.
4. Bang P. Serum proteolysis of IGFBP-3. Prog Growth Factor Res. 1995;6:285-292.
5. Bang P, Fielder PJ. Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology. 1997;138:3912-3917.
6. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med. 2001;7:59-64.
7. Harada T, Kano T, Katayama Y, Matsuzaki T, Tejima E, Koshinaga M. Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model. Thromb Haemost. 2005;94:791-796.
8. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228-231.
9. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, Carmeliet P, Weiss MH, Zlokovic BV. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler Thromb Vasc Biol. 1999;19:2801-2806.
10. Klein GM, Li H, Sun P, Buchan AM. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology. 1999;52:1381-1384.
11. Kilic E, Bahr M, Hermann DM. Effects of recombinant tissue plasminogen activator after intraluminal thread occlusion in mice: role of hemodynamic alterations. Stroke. 2001;32:2641-2647.
12. Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, Lo EH. Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 1999;19:1316-1321.
13. Lassarre C, Binoux M. Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. Endocrinology. 1994;134:1254-1262.
14. Kahles T, Foerch C, Sitzer M, Schroeter M, Steinmetz H, Rami A, Neumann-Haefelin T. Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: Relevance of interactions between thrombotic material and thrombolytic agent. Vasc Pharmacol. 2005;43:254-259.
15. Petty MA, Wettstein JG. Elements of cerebral microvascular ischaemia. Brain Res Brain Res Rev. 2001;36:23-34.
16. Guan J, Miller OT, Waugh KM, McCarthy DC, Gluckman PD. Insulin-like growth factor-1 improves somatosensory function and reduces the extent of cortical infarction and ongoing neuronal loss after hypoxia-ischemia in rats. Neuroscience. 2001;105:299-306.
17. Cao Y, Gunn AJ, Bennet L, Wu D, George S, Gluckman PD, Shao XM, Guan J. Insulin-like growth factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J Cereb Blood Flow Metab. 2003;23:739-747.
18. Hsia AW, Sachdev HS, Tomlinson J, Hamilton SA, Tong DC. Efficacy of iv tissue plasminogen activator in acute stroke: does stroke subtype really matter? Neurology. 2003;61:71-75.
19. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke RT-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
20. Alexandrov AV, Hall CE, Labiche LA, Wojner AW, Grotta JC. Ischemic stunning of the brain: early recanalization without immediate clinical improvement in acute ischemic stroke. Stroke. 2004;35:449-452.